menu

ESA Failure in Low-Risk MDS: ESA Failure Criteria and Emerging Options to Promote Transfusion Independence

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

ESA Failure in Low-Risk MDS: ESA Failure Criteria and Emerging Options to Promote Transfusion Independence

0.25 credits
15 minutes
ReachMD Healthcare Image
Choose a format
Media formats available:
0.25 credits
Completing the pre-test is required to view this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    Lower-risk MDS is associated with impaired of quality of life, a need for transfusions, and the risk of progression to acute myeloid leukemia (AML). There are now active treatments available for selected subtypes of MDS, including lower-risk MDS-RS and MDS/MPN-RS-T. In this expert column, Dr. Rami Komrokji takes us through risk stratification and how identifying ESA failure can improve the management of patients with lower-risk MDS.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. 

    Faculty:
    Rami Komrokji, MD
    Section Head, Leukemia & MDS
    Vice Chair, Malignant Hematology
    Moffitt Cancer Center
    Tampa, FL

    Consulting Fees: AbbVie, Acceleron, Bristol- Myers Squibb/Celgene

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has nothing to disclose.
    • Nick Lombardi has no relevant relationships to report.
    • Libby Lurwick has nothing to disclose.
    • Jay Runyon has nothing to disclose.
    • Mara Siegel has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Apply criteria for ESA failure to hasten the identification of patients with lower-risk MDS refractory to ESA therapy
    • Integrate safety and efficacy data on emerging therapeutic options into treatment planning for patients with lower-risk MDS after ESA failure
    • Integrate a multidisciplinary treatment approach into the shared decision-making process in patients with lower-risk MDS to preserve health-related QoL and transfusion independence
  • Target Audience

    This activity is designed to meet the educational needs of hematologist-oncologists, hematology-oncology NP/PAs, hematology-oncology nurses, and pharmacists.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this Enduring activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the  credit commensurate with the extent of their participation in the activity. Global Learning Collaborative (GLC) designates this activity for .25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for .25 AAPA Category 1 CME credits. Approval is valid until 10/12/2023. PAs should claim only the credit commensurate with the extent of their participation in the activity. 

    Global Learning Collaborative (GLC) designates this activity for .25 contact hours/0.025 CEUs of Pharmacy contact hours.

    The Universal Activity Number for this program is JA0006235-0000-22-038-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.
    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.

  • Commercial Support

    This activity is supported by an independent educational grant from Bristol Myers Squibb.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Lower-risk MDS is associated with impaired of quality of life, a need for transfusions, and the risk of progression to acute myeloid leukemia (AML). There are now active treatments available for selected subtypes of MDS, including lower-risk MDS-RS and MDS/MPN-RS-T. In this expert column, Dr. Rami Komrokji takes us through risk stratification and how identifying ESA failure can improve the management of patients with lower-risk MDS.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. 

    Faculty:
    Rami Komrokji, MD
    Section Head, Leukemia & MDS
    Vice Chair, Malignant Hematology
    Moffitt Cancer Center
    Tampa, FL

    Consulting Fees: AbbVie, Acceleron, Bristol- Myers Squibb/Celgene

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has nothing to disclose.
    • Nick Lombardi has no relevant relationships to report.
    • Libby Lurwick has nothing to disclose.
    • Jay Runyon has nothing to disclose.
    • Mara Siegel has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Apply criteria for ESA failure to hasten the identification of patients with lower-risk MDS refractory to ESA therapy
    • Integrate safety and efficacy data on emerging therapeutic options into treatment planning for patients with lower-risk MDS after ESA failure
    • Integrate a multidisciplinary treatment approach into the shared decision-making process in patients with lower-risk MDS to preserve health-related QoL and transfusion independence
  • Target Audience

    This activity is designed to meet the educational needs of hematologist-oncologists, hematology-oncology NP/PAs, hematology-oncology nurses, and pharmacists.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this Enduring activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the  credit commensurate with the extent of their participation in the activity. Global Learning Collaborative (GLC) designates this activity for .25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for .25 AAPA Category 1 CME credits. Approval is valid until 10/12/2023. PAs should claim only the credit commensurate with the extent of their participation in the activity. 

    Global Learning Collaborative (GLC) designates this activity for .25 contact hours/0.025 CEUs of Pharmacy contact hours.

    The Universal Activity Number for this program is JA0006235-0000-22-038-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.
    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.

  • Commercial Support

    This activity is supported by an independent educational grant from Bristol Myers Squibb.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule6 Dec 2022